Patents by Inventor Kenya Shitara
Kenya Shitara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10590203Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: August 11, 2017Date of Patent: March 17, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 10131711Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: May 4, 2015Date of Patent: November 20, 2018Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Publication number: 20180030146Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: August 11, 2017Publication date: February 1, 2018Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Kazuyasu NAKAMURA, Emi HOSAKA, Akiko SHIMIZU, Masamichi KOIKE
-
Patent number: 9675625Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: June 17, 2013Date of Patent: June 13, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Patent number: 9475886Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: September 30, 2014Date of Patent: October 25, 2016Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20160108136Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 21, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Publication number: 20150315285Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: May 4, 2015Publication date: November 5, 2015Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Kazuyasu NAKAMURA, Emi HOSAKA, Akiko SHIMIZU, Masamichi KOIKE
-
Patent number: 9051371Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: March 17, 2014Date of Patent: June 9, 2015Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 8900584Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: April 22, 2013Date of Patent: December 2, 2014Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 8883981Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: July 2, 2010Date of Patent: November 11, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20140186349Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: March 17, 2014Publication date: July 3, 2014Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
-
Patent number: 8632996Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: June 8, 2012Date of Patent: January 21, 2014Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
Publication number: 20130337505Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: ApplicationFiled: March 23, 2012Publication date: December 19, 2013Applicant: KYOWA HAKKO KIRIN, CO., LTD.Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI -
Publication number: 20130295045Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: June 17, 2013Publication date: November 7, 2013Inventors: Kenya SHITARA, Rinpei NIWA, So OHTA, Yuka SASAKI, Junji KANAZAWA, Toshihiko ISHII, Shiro AKINAGA
-
Publication number: 20130273038Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: April 22, 2013Publication date: October 17, 2013Inventors: Kenya SHITARA, Kazuyasu NAKAMURA, Emi HOSAKA, Akiko SHIMIZU, Masamichi KOIKE
-
Patent number: 8491902Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: December 3, 2004Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Patent number: 8492526Abstract: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: June 22, 2011Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
Patent number: 8481039Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: GrantFiled: February 3, 2012Date of Patent: July 9, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki -
Patent number: 8313913Abstract: A method for enhancing a binding activity of an antibody composition to Fc? receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fc? receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.Type: GrantFiled: August 28, 2009Date of Patent: November 20, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kazuyasu Nakamura, Kenya Shitara
-
Publication number: 20120276090Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: ApplicationFiled: June 8, 2012Publication date: November 1, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Nobuo HANAI, Emi SHOJI, Mikiko SAKURADA, Akiko FURUYA, Kazuyasu NAKAMURA, Rinpei NIWA, Kenji SHIBATA, Motoo YAMASAKI